Other / unclassifiable — a classification, not a measurement. An on-box language model (Qwen3.6-35B-A3B-UD-Q6_K_XL, prompt version 1) read this channel’s own recent posts on 15 August 2026 and assigned it the closest of 31 fixed categories, at 97% confidence. This is a model’s judgement about what the channel is likely to be about, not a fact this register measured the way a subscriber count or a view count is measured — it can be revised on a later pass, and it carries no weight anywhere else on this page. How this classification works, and the other topics.
Channels linked by matching posts
This channel is in a group of 12 registered channels linked by matching posts, directly or through other channels in the group. This channel may share no posts with some of the channels listed below, and listed channels may share none with each other. Links are found by comparing text fingerprints across every channel on the register.
Which channel, if either, published first is deliberately not shown in this list. “First” could only mean first in our own crawl, which depends on how deep we happened to reach into each channel’s history, not on when the content was actually first posted. Our one hand-check read 45 of the highest-confidence flagged pairs against the live Telegram pages. In 18 of them the live page showed a “Forwarded from” credit that our database had no record of, so reading that pair as an unattributed copy was wrong; the check did not measure who published first. This list is ordered by subscriber count, the same as every other listing on this site, never by which channel we think came first. Near-verbatim matching has several ordinary explanations besides copying — a channel mirroring itself, an unattributed repost, or two channels independently repeating the same wire story — and this measurement cannot tell those apart. How this is measured.
43 measurements spanning 93 days, net -278. Dots are measurements; the straight line between them is drawn to join them, not to claim we know the path taken in between — snapshots are recorded only when a count changes, so gaps mean “no change observed”, never “interpolated”. The vertical axis spans 9,843–10,205 and does not start at zero.
Measurement log — every subscribers count we have recorded, most recent 20 of 43
Measured (UTC)
Subscribers
Change
7 Nov 2026, 12:56
9,885
-15
4 Nov 2026, 15:30
9,900
-8
1 Nov 2026, 12:19
9,908
-10
29 Oct 2026, 02:40
9,918
-8
26 Oct 2026, 11:37
9,926
-11
23 Oct 2026, 08:38
9,937
-11
20 Oct 2026, 03:17
9,948
-8
17 Oct 2026, 08:20
9,956
-8
14 Oct 2026, 02:36
9,964
-18
9 Oct 2026, 14:01
9,982
-21
5 Oct 2026, 06:14
10,003
-18
28 Sept 2026, 17:18
10,021
-40
17 Sept 2026, 18:20
10,061
-4
15 Sept 2026, 16:37
10,065
-3
14 Sept 2026, 02:59
10,068
-3
12 Sept 2026, 08:55
10,071
-14
10 Sept 2026, 02:39
10,085
-6
6 Sept 2026, 21:57
10,091
-1
4 Sept 2026, 08:36
10,092
-9
1 Sept 2026, 20:43
10,101
first reading
Engagement
52 posts held, back to 9 July 2026 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 53 pages of Telegram’s post history, 20 posts per page.
ERR · 30 days
36.0%
avg views ÷ 9,885 subscribers
Avg views / post
3,560
14 posts measured
Reaction rate
0.372%
reactions ÷ views · ER floor
Posts in window
15
of 52 held
ERR is average views per post over the last 30 days divided by subscribers, the definition TGStat uses, so this figure is comparable with the one you will see elsewhere. It falls structurally as a channel grows: a high ERR on a small channel and a low one on a large channel describe reach mathematics, not quality. We publish the figure and the sample it came from and pass no verdict on it.
ER is defined industry-wide as (forwards + reactions + comments) ÷ views — note the denominator is views, not subscribers. Telegram’s public web preview carries views and reactions but not forward or comment counts, so the reaction rate above is the reactions term only and is therefore a floor: the true ER for this channel is higher by an amount we have not measured and will not estimate. It is computed over the 13 of 14 measured posts that carry a reaction reading, and over those same posts' views.
What these figures were computed from
Window
Rolling 30 days · latest post in window 9 November 2026
Posts held
52 (9 July 2026 – 9 November 2026)
Views total
49,870
Reactions total
178
Forwards / comments
not exposed by the public surface — not measured, not estimated
Readings taken
10 Nov 2026, 22:31 UTC
Views are a single reading per post, taken at the time above. A post published in the last day or two is still accumulating views, which pulls the 30-day average down slightly. That is a property of the standard definition rather than a fault in it, so we keep the definition rather than “correcting” the number into something nobody can reproduce.
Precision. Telegram publishes view counts on its public widget in short form — 8.12K, 3.7M — so any reading at or above 1,000 reaches us rounded to three significant figures, and only counts below 1,000 are exact. Averages and rates derived from them are shown to the same precision rather than to the unit: a figure like 3,701,250 would assert digits nobody measured.
Reaction counts are published per emoji and rounded the same way, so a total below 1,000 is exact and a larger one is a sum that may carry a rounded component from each emoji above 1,000. Because it is a sum, it does not look rounded — read a large reaction total as three significant figures per contributing emoji rather than as the figure it prints.
What this channel posts
Photos
200
Links
444
Lifetime counters from Telegram’s own channel header, read 10 November 2026 — not the date at the top of this page, which is when the subscriber count was last read. Below Telegram’s rounding threshold, so these counts are exact.
Reaction mix
672 reactions across 43 posts, in 11 distinct kinds. The most used accounts for 33.2% of them.
Every reaction kind recorded on the sample, most used first
Reaction
Count
Share
Share, drawn
❤
223
33.2%
👍
197
29.3%
🔥
105
15.6%
👀
70
10.4%
👏
24
3.57%
🥰
21
3.13%
🎉
18
2.68%
👌
7
1.04%
🙏
4
0.595%
😁
2
0.298%
😍
1
0.149%
No sentiment is inferred, and none should be read in. This table is ordered by count and by nothing else. Emoji do not carry stable meaning across languages or communities — 🙏 is thanks in one channel and mourning in another — so we publish which ones were pressed and how often, and pass no judgement on what an audience meant by them.
Precision. Telegram publishes reaction counts per emoji and short-forms each one — 4.34K, 1.2M — so any single kind at or above 1,000 reaches us at three significant figures, and only counts below 1,000 are exact. The shares above are ratios of those figures and carry the same error. This is also why the total here can differ slightly from a reaction total printed elsewhere on the page: both are sums of the same rounded parts, taken over samples with different edges.
Coverage. Reactions were read on 46 of the 52 sampled posts in this sample. Summed by Telegram’s own count on each post — not by adding up the per-emoji breakdown above — those same posts carry 725 reactions in total: the kind of figure the paragraph above means by “a reaction total printed elsewhere on the page”.
Measured over the 52 most recent posts we hold, published 9 July 2026 to 9 November 2026, using the newest reading held for each. Telegram Stars are excluded: they are a payment, not a reaction, and they have their own section.
Recent posts
Telegram’s own ‘edited’ marker: 0 of 15 posts held from the last 30 days (0%) carried it when this register last read them. The marker says a post was changed after publishing, not what it said before — this register holds the earlier wording only where an edit fell between two of its own reads (see the edit ledger and how it is measured).
리가켐바이오가 이제 윤곽이 드러나기 시작한 CLDN18.2 ADC 경쟁 속에서, 후발주자로서 내세우고 있는 메시지는 분명합니다. TOP1 저해제 페이로드(payload) 기반 ADC ‘LCB02A’의 포지셔닝을 1차치료제로 포커스하고 있고, 그러면 ‘어떻게 갈 것인가’가 그다음 질문입니다.
이번 ESMO 2026의 하이라이트 중 하나는 CLDN18.2 ADC였습니다. 아스트라제네카의 ‘소네베(sone-ve)’의 위암 2·3차 치료제 글로벌 임상2/3상 결과, 그리고 다케다가 1년전 베팅한 중국 이노벤트(Innovent)의 ‘알코타툭 타바테칸(arcotatug tavatecan)’를 3차이상 치료제 세팅에서 평가한 일본과 중국 임상3상 데이터가 공개됐습니다. 메시지는 크게 2가지였는데, 두 임상 모두에서 40~50% 수준의 OS 개선 효과를 …
[보도자료] 리가켐바이오, ‘BIO-Europe 2026’·‘제프리스 글로벌 헬스케어 컨퍼런스’ 연이어 참가…글로벌 파트너링 논의 가속화
- 11월 9~11일 독일 쾰른 ‘BIO-Europe 2026’서 글로벌 제약사와 다수의 1:1 파트너링 미팅 진행
- 자체 개발 임상·전임상 단계 파이프라인 및 차세대 ADC 플랫폼 기술이전 논의 예정
- 11월 16~19일 영국 런던 ‘제프리스 컨퍼런스’서 글로벌 투자자·제약사 대상 ‘자체 개발+파트너링’ 투트랙 전략 소개
㈜리가켐바이오사이언스(KOSDAQ: 141080, 이하 ‘리가켐바이오’)는 이달 9일부터 11일까지(현지 시간) 독일 쾰른에서 열리는 유럽 최대 바이오 파트너링 행사 ‘BIO-Europe 2026’과 16일부터 19일까지 영국 런던에서 열리는 ‘제프리스 글로벌 헬스케어 컨퍼런스’에 …
[리가켐바이오 2026년 3분기 실적발표 및 R&D 업데이트 컨퍼런스콜 안내]
안녕하세요, 리가켐바이오 IR팀입니다.
2026년 3분기 경영실적과 R&D 현황을 소개하는 컨퍼런스콜을 아래와 같이 진행합니다.
■ 일시: 2026년 11월 13일(금) 16:00~17:00 (한국시간)
■ 방식: 컨퍼런스콜 및 웹캐스팅
■ 주요 내용
· 2026년 3분기 경영실적
· 주요 파이프라인 R&D 현황
· 향후 주요 일정 및 사업계획
· 질의응답(Q&A)
■ 참여 방법: 아래 링크에서 사전 또는 당일 등록 후 행사 당일 청취 및 자료 다운로드 가능
https://irsvc.teletogether.com/lcb/lcb2026Q3_kor.php
■ IR 자료: 행사 당일 KIND 및 당사 홈페이지(Investors > IR 자료) 게재 예정
많은 관…
2026.11.05 13:40:51
기업명: 리가켐바이오(시가총액: 2조 3,850억) A141080
보고서명: 기업설명회(IR)개최
개최일자 : 2026-11-13
개최시각 : 16:00
*IR 목적
2026년 3분기 경영실적 및 R&D 업데이트 발표
*IR 내용
- 2026년 3분기 경영실적 - 주요 파이프라인 R&D 현황 - 향후 주요 일정 및 사업계획 - 질의응답(Q&A)
공시링크: https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20261105900327
종목공시 : https://www.awakeplus.co.kr/disclosure/141080
조금 전 공유드린 보도자료 내용 중,
"공개되는 초록에 따르면 2026년 7월 데이터 컷오프 기준 효능 평가가 가능한 17명 중 9명에서 반응이 나타나 객관적반응률(ORR) 53%를 기록했으며, 5명(29%)은 완전대사반응을 보였다. 반응은 최저 용량을 포함한 모든 코호트에서 관찰됐으며, 공격성 림프종 환자는 물론 CAR-T 치료 경험 여부와 관계없이 나타났다. 특히 CD19 표적 CAR-T 치료 경험 환자 4명 중 3명(ORR 75%)이 반응을 보여, 기존 치료 옵션이 소진된 환자군에서도 효능 가능성을 확인했다."
—————————————
아직 용량증대 중인 임상에서 목표하고 있는 최고용량 수준에 도달하지 않았음에도 불구하고 완전대사반응(CR, 완전관해에 해당)가 29% 환자에게서 확인됐다는점, 그리고 CAR-T 치료 경험 환자들에게서…
[보도자료] 리가켐바이오, ASH 2026서 CD19 ADC ‘IKS03’ 긍정적 임상 중간 결과 및 CD33 ADC ‘LCB122A’ 전임상 성과 최초 공개
- IKS03, 다수의 사전 치료를 받은 B세포 림프종 환자 ORR 53%…최저 용량 포함 모든 코호트에서 반응 확인
- 최대내약용량(MTD) 미도달…낮은 호중구감소증 발생률 등 우수한 안전성 확인
- 리가켐바이오, 자체 개발 CD33 ADC ‘LCB122A’ 최초 공개…자사 첫 DAR1 ADC로 효능 및 안전성 개선 가능성 확인
㈜리가켐바이오사이언스(KOSDAQ: 141080, 이하 ‘리가켐바이오’)는 파트너사 익수다 테라퓨틱스(IKSUDA Therapeutics, 이하 ‘익수다’)가 자사로부터 도입해 개발 중인 CD19 표적 항체-약물 결합체(이하 ‘ADC’) ‘IKS03(LCB7…
리가켐바이오 IR/PR 공식 채널 pinned «[보도자료] 리가켐바이오 플랫폼 적용 ‘IKS014’, 엔허투 치료 경험 유방암서 ORR 50%·우수한 안전성…SABCS 발표 - 엔허투 치료 경험이 있는 HER2 양성 유방암 환자군에서 ORR 50%…18개월 이상 지속 반응도 확인 - ‘엔허투 이후(post-Enhertu)’ HER2 ADC 단독요법 중 현재까지 공개된 데이터 기준 최고 수준의 반응률 - 리가켐바이오 ADC 플랫폼 ‘콘쥬올(ConjuAll™)’ 기반…범종양(pan-tumor) 임상 1상에서…»
[리가켐바이오] 엔허투 이후 HER2 ADC, 왜 어려운가. 최신 MD앤더슨 연구와 IKS014
📄 지난 10월 국제 학술지 Breast Cancer Research에 미국 MD앤더슨 암센터의 연구가 게재됐습니다. 엔허투 치료 후 질환이 진행된 전이성 유방암 환자에게 캐싸일라(T-DM1)를 투여한 결과를 분석한 연구입니다.
▪️ 대상: 엔허투 치료 후 캐싸일라를 투여받은 환자 21명 (후향 분석)
▪️ 객관적반응률(ORR): 0% (완전·부분반응 없음)
▪️ 무진행생존기간(PFS) 중앙값: 2.2개월
연구진은 엔허투 이후 기존 HER2 ADC를 순차 투여할 때 효과가 매우 제한적이라는 점을 확인했습니다. 엔허투가 1차 치료로 확대되면서 '엔허투 이후' 환자군은 계속 늘고 있지만, 아직 확립된 표준치료가 없습니다.
💡 리가켐바이오-익수다…
[보도자료] 리가켐바이오 플랫폼 적용 ‘IKS014’, 엔허투 치료 경험 유방암서 ORR 50%·우수한 안전성…SABCS 발표
- 엔허투 치료 경험이 있는 HER2 양성 유방암 환자군에서 ORR 50%…18개월 이상 지속 반응도 확인
- ‘엔허투 이후(post-Enhertu)’ HER2 ADC 단독요법 중 현재까지 공개된 데이터 기준 최고 수준의 반응률
- 리가켐바이오 ADC 플랫폼 ‘콘쥬올(ConjuAll™)’ 기반…범종양(pan-tumor) 임상 1상에서 개선되고 차별화된 안전성 프로파일 구현
㈜리가켐바이오사이언스(KOSDAQ: 141080, 이하 ‘리가켐바이오’)는 파트너사인 익수다 테라퓨틱스(IKSUDA Therapeutics, 이하 ‘익수다’)가 중화권 및 한국을 제외한 글로벌 독점 권리를 자사로부터 확보해 개발 중인 HER2 표적…
[보도자료] 리가켐바이오, ESMO 2026서 위암·췌장암 ADC 'LCB02A' 성과 공개
아직 승인 ADC 없는 CLDN18.2 표적…전임상 효과 확인하고 글로벌 임상 돌입
■ 위암·췌장암 세포만 골라 공격…정상세포에는 영향 미미
■ 동물실험서 1회 투여만으로 종양 성장 억제…안전성도 양호
■ 기존 치료제 사용 후 병이 진행된 환자까지 포함한 글로벌 임상 설계 공개
㈜리가켐 바이오사이언스(141080KS, 이하 ‘리가켐바이오’)는 23일(현지시간)부터 27일까지 스페인 마드리드에서 열리고 있는 유럽종양학회 연례학술대회 ‘ESMO Congress 2026’에서 항체-약물 결합체(ADC) 'LCB02A'의 전임상 연구 결과와 글로벌 임상 계획을 담은 포스터 2건을 공개했다고 26일 밝혔다.
LCB02A는 위암·췌장암 등에…
❤8👀1
Showing the 12 most recent of 52 posts we hold for @SHIDGL. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.
Forward network
Republished by
Channels on the register that have forwarded this channel's posts into their own feed.
Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.
Mentions
Named by 2 registered channels — every channel on the register whose own posts have named this one, by its current username or any other username it currently holds, merged from two separately captured readings of the same fact so a namer caught by only one of them is not missed and a namer both caught is not counted twice. A username this channel has since dropped is not matched — that handle may belong to someone else now, and crediting today’s namer to yesterday’s owner would misattribute it.
Named by
Channels on the register whose posts name this channel's handle.
A mention is a weaker signal than a forward and is counted separately for that reason — naming a channel is not republishing it, and a handle in a post body is easy to place deliberately. The post counts beside each row below are distinct posts in which the handle appeared, from posts we have read on both sides — the “Named by N registered channels” figure above is a different count, of distinct NAMING CHANNELS rather than posts, and is not the sum of the rows under it.
Appears in Telegram’s recommendations for other channels
The reverse of the list above, and a different kind of signal. This does not require this channel to have ever been asked about directly — each row below is a channel we DID ask Telegram about, whose Telegram-generated list happened to include this one. A channel can appear here with an empty list above it, because being named by someone else’s query is independent of having been queried itself.
허혜민의 제약/바이오 소식통 @huhpharm · 24,265 Telegram ranks this channel #10 of 93 here — alongside 92 others — read 16 September 2026
유진투자증권 코스닥벤처팀 @SmallCap · 22,994 Telegram ranks this channel #76 of 96 here — alongside 95 others — read 19 September 2026
실시간 주식 뉴스 @realtime_stock_news · 36,964 Telegram ranks this channel #86 of 93 here — alongside 92 others — read 2 September 2026
이지스스트레티지 리서치 @jeilstock · 26,244 Telegram ranks this channel #90 of 93 here — alongside 92 others — read 12 September 2026
가치투자클럽 @corevalue · 67,126 Telegram ranks this channel #90 of 93 here — alongside 92 others — read 2 September 2026
[메리츠 Tech 김선우, 양승수, 김동관] @merITz_tech · 24,795 Telegram ranks this channel #91 of 92 here — alongside 91 others — read 17 September 2026
키움증권 미국주식 톡톡 @kwusa · 36,213 Telegram ranks this channel #91 of 92 here — alongside 91 others — read 2 September 2026
This channel appears in 7 seed channels' Telegram-generated recommendation lists in total. Each is Telegram’s list for THAT channel, not this one — see how this is measured.
Cite this entry
A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 7 November 2026 — this
entry's latest reading, not the date you are reading this.
“리가켐바이오 IR/PR 공식 채널” (@SHIDGL), 9,885 subscribers as measured 7 November 2026. Telegram Register, tgregister.com/channel/SHIDGL.
Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.